0.00Open0.57Pre Close0 Volume532 Open Interest260.00Strike Price0.00Turnover50.83%IV11.34%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.57Extrinsic Value100Contract SizeAmericanOptions Type0.0780Delta0.0088Gamma410.60Leverage Ratio-0.1642Theta0.0035Rho32.02Eff Leverage0.0478Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet